Literature DB >> 20460546

Update on pulmonary hypertension 2009.

Mark T Gladwin1, Hossein-Ardeschir Ghofrani.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20460546      PMCID： PMC3269229          DOI： 10.1164/rccm.201002-0235UP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  49 in total

1.  Imatinib for the treatment of pulmonary arterial hypertension.

Authors:  Hossein A Ghofrani; Werner Seeger; Friedrich Grimminger
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  Long term imatinib treatment in pulmonary arterial hypertension.

Authors:  R Souza; O Sitbon; F Parent; G Simonneau; M Humbert
Journal:  Thorax       Date:  2006-08       Impact factor: 9.139

3.  Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.

Authors:  Karen C Patterson; Ariel Weissmann; Tahamtan Ahmadi; Harrison W Farber
Journal:  Ann Intern Med       Date:  2006-07-18       Impact factor: 25.391

4.  Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects.

Authors:  B M McQuillan; M H Picard; M Leavitt; A E Weyman
Journal:  Circulation       Date:  2001-12-04       Impact factor: 29.690

5.  Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation.

Authors:  K Okada; M L Bernstein; W Zhang; D P Schuster; M D Botney
Journal:  Am J Respir Crit Care Med       Date:  1998-09       Impact factor: 21.405

6.  Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension.

Authors:  Jean-Paul Richalet; Pierre Gratadour; Paul Robach; Isabelle Pham; Michèle Déchaux; Aude Joncquiert-Latarjet; Pascal Mollard; Julien Brugniaux; Jérémy Cornolo
Journal:  Am J Respir Crit Care Med       Date:  2004-10-29       Impact factor: 21.405

7.  Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.

Authors:  R Kessler; M Faller; G Fourgaut; B Mennecier; E Weitzenblum
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

8.  Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.

Authors:  Hossein A Ghofrani; Frank Reichenberger; Markus G Kohstall; Eike H Mrosek; Timon Seeger; Horst Olschewski; Werner Seeger; Friedrich Grimminger
Journal:  Ann Intern Med       Date:  2004-08-03       Impact factor: 25.391

9.  Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma.

Authors:  Gabor Kovacs; Robert Maier; Elisabeth Aberer; Marianne Brodmann; Stefan Scheidl; Natascha Tröster; Christian Hesse; Wolfgang Salmhofer; Winfried Graninger; Ekkehard Gruenig; Lewis J Rubin; Horst Olschewski
Journal:  Am J Respir Crit Care Med       Date:  2009-08-13       Impact factor: 21.405

Review 10.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694
View more
  6 in total

Review 1.  Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.

Authors:  Brian S Zuckerbraun; Patricia George; Mark T Gladwin
Journal:  Cardiovasc Res       Date:  2010-12-22       Impact factor: 10.787

2.  Pulmonary arterial hypertension: advances in pathophysiology and management.

Authors:  Sandeep Chopra; Dinesh K Badyal; P Chris Baby; Davis Cherian
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

3.  Enhancer of zeste homolog 2 induces pulmonary artery smooth muscle cell proliferation.

Authors:  Salman A Aljubran; Ruan Cox; Prasanna Tamarapu Parthasarathy; Gurukumar Kollongod Ramanathan; Venugopal Rajanbabu; Huynh Bao; Shyam S Mohapatra; Shyam M Mohapatra; Richard Lockey; Narasaiah Kolliputi
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

4.  Pulmonary hypertension among 5 to 18 year old children with sickle cell anaemia in Nigeria.

Authors:  Ogochukwu J Sokunbi; Ekanem N Ekure; Edamisan O Temiye; Roosevelt Anyanwu; Christy A N Okoromah
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

5.  Right ventricular function among South East Nigeria children with sickle cell anaemia.

Authors:  Josephat M Chinawa; Bartholomew F Chukwu; Awoere T Chinawa; Edmund N Ossai; Anthony N Ikefuna; Ann E Aronu; Egbuna O Obidike
Journal:  BMC Pediatr       Date:  2020-05-21       Impact factor: 2.125

6.  Pulmonary hypertension and right ventricular function in Nigerian children with sickle cell anaemia.

Authors:  Igoche D Peter; Mustafa O Asani; Shehu U Abdullahi; Ibrahim Aliyu; Stephen K Obaro; Fidelia Bode-Thomas
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-08-01       Impact factor: 2.184
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.